top of page
The Professional Network for Healthcare Experts
FDA proposes streamlined nonclinical safety studies for antibody-drug conjugates and other oncology biologics
The draft guidance could reduce reliance on animal studies for some oncology products while increasing the importance of analytical characterisation and weight-of-evidence approaches during development.
nuaxia
Aug 72 min read
Pathos AI licenses first-in-class bispecific ADC JSKN016 from Alphamab Oncology in deal worth up to $4.8 billion
Pathos AI licenses first-in-class bispecific ADC JSKN016 from Alphamab Oncology in deal worth up to $4.8 billion
nuaxia
Aug 62 min read
Kelun’s Merck-Partnered ADC Delivers Phase III Win in First-Line PD-L1-Negative Lung Cancer
Sacituzumab tirumotecan plus Keytruda improves progression-free survival in advanced NSCLC, expanding potential role of ADC-immunotherapy combinations.
nuaxia
Jul 173 min read
Novartis Acquires Myricx Bio in Up to $1.5bn Deal to Strengthen ADC Pipeline
The acquisition adds a novel antibody-drug conjugate payload platform and two preclinical oncology programmes targeting hard-to-treat solid tumours.
nuaxia
Jul 73 min read
bottom of page